Rein Therapeutics insider files 5.8% stake disclosure

Rein Therapeutics, Inc. disclosure: Laurence W. Lytton reports beneficial ownership of 4,500,000 shares of Common Stock, representing 5.8% of the class.

Rhea-AI Filing Summary

Rein Therapeutics, Inc. disclosure: Laurence W. Lytton reports beneficial ownership of 4,500,000 shares of Common Stock, representing 5.8% of the class. The filing cites 78,039,032 shares outstanding following the issuer's issuance and sale of 50,000,000 shares as reported in a Rule 424(b)(5) prospectus.

Insights

Governance Specialist

Single investor reports a 5.8% beneficial stake after a large issuance.

The filing shows Laurence W. Lytton beneficially owns 4,500,000 shares, with sole voting and dispositive power. The ownership percentage is calculated on 78,039,032 shares outstanding following an issuer sale of 50,000,000 shares.

Holder disclosures at this scale are public ownership signals; subsequent Form 13 filings or transactions would update the ownership picture.

Key Figures

Beneficial ownership: 4,500,000 shares Percent of class: 5.8% Shares outstanding: 78,039,032 shares +2 more

5 metrics

Beneficial ownership 4,500,000 shares Amount beneficially owned reported by Laurence W. Lytton

Percent of class 5.8% Percent of Common Stock as reported in the filing

Shares outstanding 78,039,032 shares Shares outstanding used to calculate percentage following issuer issuance

Issuer sale reported 50,000,000 shares Issuer's issuance and sale referenced from Rule 424(b)(5) prospectus

CUSIP 00887A204 CUSIP for Rein Therapeutics Common Stock

Key Terms

Schedule 13G, beneficial ownership, Rule 424(b)(5) prospectus

3 terms

Schedule 13G regulatory

"Item 2. (a) Name of person filing: Laurence W. Lytton"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial ownership financial

"Item 4. Ownership (a) Amount beneficially owned: 4,500,000"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Rule 424(b)(5) prospectus regulatory

"calculated based on 78,039,032 shares of Common Stock outstanding following the completion of the Issuer's issuance"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake did Laurence W. Lytton report in Rein Therapeutics (RNTX)?

He reported beneficial ownership of 4,500,000 shares, equal to 5.8% of the class. This percentage uses 78,039,032 shares outstanding after the issuer sold 50,000,000 shares reported in a Rule 424(b)(5) prospectus.

How many Rein Therapeutics shares were outstanding for the ownership calculation?

The filing states 78,039,032 shares outstanding as the basis for the percentage. That outstanding count follows the issuer's reported issuance and sale of 50,000,000 shares in a prospectus dated May 4, 2026.

Does Lytton have voting or dispositive power over the reported shares?

Yes. The filing shows sole voting power and sole dispositive power over 4,500,000 shares. No shared voting or dispositive powers are reported in the disclosed table.

What document underlies the shares-outstanding figure cited in the filing?

The percentage comment references a Rule 424(b)(5) prospectus filed May 4, 2026. That prospectus reported the issuer's issuance and sale of 50,000,000 shares used to derive the 78,039,032 outstanding count.

Will this Schedule 13G trigger further disclosure obligations for Lytton?

This filing reports passive beneficial ownership at the disclosed level. Any material change in ownership above reporting thresholds would require updated filings under applicable SEC rules; subsequent filings would show such changes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 01:29 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Rein Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00887A204

(CUSIP Number)

05/01/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00887A204

1

Names of Reporting Persons

LYTTON LAURENCE W

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,500,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,500,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The percentage reported herein is calculated based on 78,039,032 shares of Common Stock outstanding following the completion of the Issuer's issuance and sale of 50,000,000 shares of Common Stock, as reported in the Rule 424(b)(5) Prospectus filed by the issuer on May 4, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Rein Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758
Item 2.
(a)	Name of person filing: Laurence W. Lytton
(b)	Address or principal business office or, if none, residence: 467 Central Park West New York, NY 10025
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 00887A204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,500,000
(b)	Percent of class: 5.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,500,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,500,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

LYTTON LAURENCE W

Signature:	/s/ Laurence W Lytton
Name/Title:	Reporting Person
Date:	05/06/2026